Cortisol levels in bodily fluids represent a useful index for pituitary adrenal function, and thus practical anti-cortisol antibodies are required. We have studied "antibody-breeding" approaches, which involve in vitro evolution of antibodies to improve their antigen-binding performances. Here, we produced an antibody fragment to measure serum cortisol levels with over 30-fold enhanced affinity after single mutagenesis and selection steps. A mouse anti-cortisol antibody, Ab-CS#3, with insufficient affinity for practical use, was chosen as the prototype antibody. A "wild-type" single-chain Fv fragment (wt-scFv; K a , 3.4 10 8 M 1 ) was prepared by bacterial expression of a fusion gene combining the V H and V L genes for this antibody. Then, random point mutations were generated separately in V H or V L by error-prone PCR, and the resulting products were used to assemble scFv genes, which were displayed on filamentous phages. Repeated panning of the phage library identified a mutant scFv (scFv#m1-L10) with an over 30-fold enhanced affinity (K a 1.2 10 10 M 1 ). Three amino acid substitutions (Cys49Ser, Leu54Pro, and Ser63Gly) were observed in its V L sequence. In a competitive enzyme-linked immunosorbent assay (ELISA), the mutant scFv generated doseresponse curves with measuring range ca. 0.03-0.6 ng/assay cortisol, midpoint of which (0.15 ng/assay) was 7.3-fold lower than that of wt-scFv. Although cortisone, 11-deoxycortisol, and prednisolone showed considerable cross-reactivity, the mutant scFv should enable sensitive routine cortisol assays, except for measurement after metyrapone or high-dose of prednisolone administrations. Actually, cortisol levels of control sera obtained with the scFv-based ELISA were in the reference range.Key words antibody; single-chain Fv fragment; cortisol; in vitro evolution; affinity maturation; enzymelinked immunosorbent assay Immunoassays are essential tools for monitoring various biomarkers in bodily fluids because of the excellent specificity conferred by antigen−antibody reactions. 1) Currently, most diagnostic antibodies are produced by B-cell hybridoma technology, 2,3) which generates "native" antibodies (in vivo antibodies) induced in animals by immunization as cloned products ensuring constant binding abilities. However, the limited B-cell clone repertoire in mammals often prevents the generation of antibodies with practical performance. In particular, the equilibrium affinity constant (K a ) of antibodies against small biomarkers (i.e., haptenic compounds) rarely exceeds the 10 10 M −1 range.
4,5)We have employed an "antibody-breeding" approach to overcome this limitation inherent to native antibodies and to enable subfemtomole detection of small molecules. 5) Using this approach, the antigen-binding affinity can be enhanced by in vitro mutagenesis and subsequent selection of improved species (i.e., in vitro affinity maturation).3,5-9) Typically, the antibody of interest is converted to the corresponding singlechain Fv fragment (scFv) [10][11][12] or Fab fragment (Fab) by ...